These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33129491)

  • 41. Bayesian monitoring of phase II trials in cancer chemoprevention.
    Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
    J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.
    Thall PF; Sung HG
    Stat Med; 1998 Jul; 17(14):1563-80. PubMed ID: 9699230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bayesian predictive approach for inference about proportions.
    Lecoutre B; Derzko G; Grouin JM
    Stat Med; 1995 May 15-30; 14(9-10):1057-63; discussion 1064. PubMed ID: 7569500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adaptive Bayesian randomized trials: realizing their potential.
    Pullenayegum EM
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():29-33. PubMed ID: 22810444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An introduction to the use of interim data analyses in clinical trials.
    Lewis RJ
    Ann Emerg Med; 1993 Sep; 22(9):1463-9. PubMed ID: 8363121
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials.
    Zhong W; Koopmeiners JS; Carlin BP
    Contemp Clin Trials; 2013 Nov; 36(2):587-96. PubMed ID: 23583925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information.
    Rufibach K; Jordan P; Abt M
    J Biopharm Stat; 2016; 26(2):191-201. PubMed ID: 25372950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Best uses of
    Quatto P; Ripamonti E; Marasini D
    J Biopharm Stat; 2020; 30(1):121-142. PubMed ID: 31264506
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Using Bayesian statistics to estimate the likelihood a new trial will demonstrate the efficacy of a new treatment.
    Biau DJ; Boulezaz S; Casabianca L; Hamadouche M; Anract P; Chevret S
    BMC Med Res Methodol; 2017 Aug; 17(1):128. PubMed ID: 28830464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II trial design with Bayesian adaptive randomization and predictive probability.
    Yin G; Chen N; Lee JJ
    J R Stat Soc Ser C Appl Stat; 2012 Mar; 61(2):219-35. PubMed ID: 24259753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.
    Thall PF; Simon RM; Estey EH
    Stat Med; 1995 Feb; 14(4):357-79. PubMed ID: 7746977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bayesian designs with frequentist and Bayesian error rate considerations.
    Wang YG; Leung DH; Li M; Tan SB
    Stat Methods Med Res; 2005 Oct; 14(5):445-56. PubMed ID: 16248347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bayesian interim analysis of phase II cancer clinical trials.
    Heitjan DF
    Stat Med; 1997 Aug; 16(16):1791-802. PubMed ID: 9280033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials.
    Sherry AD; Msaouel P; Miller AM; Lin TA; Kupferman GS; Jaoude JA; Kouzy R; El-Alam MB; Patel R; Koong A; Lin C; Meirson T; McCaw ZR; Ludmir EB
    medRxiv; 2024 Jun; ():. PubMed ID: 38978666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Practical approaches to Bayesian sample size determination in non-inferiority trials with binary outcomes.
    Turner RM; Clements MN; Quartagno M; Cornelius V; Cro S; Ford D; Tweed CD; Walker AS; White IR
    Stat Med; 2023 Apr; 42(8):1127-1138. PubMed ID: 36661242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.
    Saville BR; Connor JT; Ayers GD; Alvarez J
    Clin Trials; 2014 Aug; 11(4):485-493. PubMed ID: 24872363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Airtraq® reduces the hemodynamic response to tracheal intubation using single-lumen tubes in adults compared with the Macintosh laryngoscope: A systematic review and meta-analysis of randomized control trials.
    Hoshijima H; Maruyama K; Mihara T; Mieda T; Shiga T; Nagasaka H
    J Clin Anesth; 2018 Jun; 47():86-94. PubMed ID: 29635148
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part II: Bayesian Approaches.
    Smania G; Baiardi P; Ceci A; Cella M; Magni P
    CPT Pharmacometrics Syst Pharmacol; 2016 Aug; 5(8):402-10. PubMed ID: 27530374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predicting clinical trial results based on announcements of interim analyses.
    Broglio KR; Stivers DN; Berry DA
    Trials; 2014 Mar; 15():73. PubMed ID: 24607270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.